|
|
Post by sportsrancho on Mar 3, 2021 21:56:18 GMT -5
Ok❣️Mango...You got it ..wait till you see what’s coming next:-)) #ExtensiveGraphs
|
|
|
|
Post by morfu on Mar 4, 2021 9:22:51 GMT -5
White Paper – The Vdex Protocol in a Significant Sample of Patients January, 2021 Each patient presented to Vdex after being referred from another physician where their level of blood glucose control was much worse. None were newly diagnosed by Vdex. Generally, the referring physicians had followed the ADA-recognized treatment protocol. These results occurred only after patients were switched to the Vdex protocol. static1.squarespace.com/static/5a37ff648fd4d234be3cea06/t/60400c9918ca0e632a67ee4f/1614810265923/White-Paper-4-The-Vdex-Protocol-in-a-Larger-Sample.pdfA different solution to the problem is necessary. A real solution would bring the patient’s HbA1c below about 6.3 where vascular damage is much reduced. A real solution would bring the patient’s HbA1c down to the normal range in many cases. That’s how one really tames the disease of diabetes. The Vdex protocol appears to be that real solution. Having now applied its protocol to a wider patient population, Vdex has seen no obstacles to broad adoption among people with diabetes, other than insurance coverage for the main therapeutic agent, Afrezza. Note however, that Vdex is fully compensated for its medical services in treating patients. Even if an insurance plan ultimately denies coverage for the therapy, the medical provider is compensated for its services. The most striking feedback from patients was their gratitude. They had finally found someone who could control their disease. They could finally stop being consumed by thinking and dealing with their diabetes. A number commented that they had never thought they could feel so good. Others said they no longer felt diabetic. Some simply broke down in tears. Every patient should have the option of the Vdex protocol. Very impressive. I always enjoy the Vdex White Papers, and appreciate Vdex disclosing this information. The results are very impressive, but not unexpected since we already know how effective Vdex is at diabetes care. My only complaint is there is no CGM graphs. I always really like the graphs in the Vdex White Papers. Bring back the graphs 🙂 >> Very impressive. Not really! All it shows is that Afrezza (and their other technologies) works! What is missing here is data proofing the claims, that they contribute significantly to Afrezza patient numbers (the study is about 76 patients for a whole year) and at the same time their retention rate is higher than other Afrezza patients.
|
|
|
|
Post by sportsrancho on Mar 4, 2021 10:14:12 GMT -5
|
|
|
|
Post by bones1026 on Mar 4, 2021 10:32:39 GMT -5
Companies over 5B MC..were not even close |
|
|
|
Post by mnkdnewbie on Mar 4, 2021 10:42:31 GMT -5
Hate to be a debbie downer but this appears to be the usual rinse and repeat. I'm preparing to back up the truck when PPS goes below $2 and load up again.
|
|
|
|
Post by sportsrancho on Mar 4, 2021 10:46:41 GMT -5
Companies over 5B MC..were not even close Art Cashin is talking about this ETF right now and he says it’s based off Stock Twits🤣 |
|
|
|
Post by factspls88 on Mar 4, 2021 10:51:41 GMT -5
The drug is RARELY COVERED. We have to fight like hell to get plans to cover. See MNKD can only advocate for Afrezza in accordance with ADA treatment protocol but used that way Afrezza doesn’t impress and is not likely covered. Our way we need to argue for an exception each time bc not in accordance with ADA. But we get it done. We know exactly how to get the results we need to get it covered. Afrezza is really better then most could ever imagine. Like Bills says, it’s hard for the doctors to even get their head around the results from this drug if used to its optimal potential. Thank you for all of the great feedback, Sports. There is so much more to do to make Afrezza successful. It seems to me that Vdex is a great model, but issues remain such as expanding geography, driving doctors to refer patients to Vdex, educating patients and making Afrezza affordable. Has any thought been given to developing a virtual model to expand Vdex's reach, providing live interface between the patient and Vdex doctors/nurses to provide the training needed and personnel to secure insurance coverage? It would be a huge undertaking, I know, and of course investment would be required. |
|
|
|
Post by longliner on Mar 4, 2021 10:51:56 GMT -5
Companies over 5B MC..were not even close Art Cashin is talking about this ETF right now and he says it’s based off Stock Twits🤣 Now that's the tail wagging the dog.  |
|
|
|
Post by sportsrancho on Mar 4, 2021 11:19:13 GMT -5
The drug is RARELY COVERED. We have to fight like hell to get plans to cover. See MNKD can only advocate for Afrezza in accordance with ADA treatment protocol but used that way Afrezza doesn’t impress and is not likely covered. Our way we need to argue for an exception each time bc not in accordance with ADA. But we get it done. We know exactly how to get the results we need to get it covered. Afrezza is really better then most could ever imagine. Like Bills says, it’s hard for the doctors to even get their head around the results from this drug if used to its optimal potential. Thank you for all of the great feedback, Sports. There is so much more to do to make Afrezza successful. It seems to me that Vdex is a great model, but issues remain such as expanding geography, driving doctors to refer patients to Vdex, educating patients and making Afrezza affordable. Has any thought been given to developing a virtual model to expand Vdex's reach, providing live interface between the patient and Vdex doctors/nurses to provide the training needed and personnel to secure insurance coverage? It would be a huge undertaking, I know, and of course investment would be required. Good points. We’re already doing a small version of that with telehealth. It’ll grow as will our physical locations. We also have hospital endorsements from Las Cruces MN. |
|
|
|
Post by mymann on Mar 4, 2021 13:32:16 GMT -5
What I would like to know is how does Vdex make money with such a low volume patient traffic?
|
|
|
|
Post by mango on Mar 4, 2021 14:53:30 GMT -5
Very impressive. I always enjoy the Vdex White Papers, and appreciate Vdex disclosing this information. The results are very impressive, but not unexpected since we already know how effective Vdex is at diabetes care. My only complaint is there is no CGM graphs. I always really like the graphs in the Vdex White Papers. Bring back the graphs 🙂 >> Very impressive. Not really! All it shows is that Afrezza (and their other technologies) works! What is missing here is data proofing the claims, that they contribute significantly to Afrezza patient numbers (the study is about 76 patients for a whole year) and at the same time their retention rate is higher than other Afrezza patients.
The report told us— Average starting HbA1c: 10.4 Average lowest HbA1c attained: 6.6 Total drop in HbA1c: 3.8 in about 104 days. That is significant. All done using Afrezza. Sure, CGMs help guide the patient, but it is the Afrezza that is doing the magic. Also something else pretty remarkable worth mentioning from the report is: While these gross numbers are impressive, perhaps more impressive is that 72% of patients attained an HbA1c of 7 or below. Majority of PWD don’t reach that level, which is set by ADA, and is actually still much too high as it is still in the red zone for microvascular damage, oxidative stress and so on. Vdex goes beyond the proven treat to failure protocols of ADA. |
|
|
|
Post by sportsrancho on Mar 4, 2021 18:21:04 GMT -5
What I would like to know is how does Vdex make money with such a low volume patient traffic? From White Paper.. “Note however, that Vdex is fully compensated for its medical services in treating patients. Even if an insurance plan ultimately denies coverage for the therapy, the medical provider is compensated for its services.” |
|
|
|
Post by sportsrancho on Mar 4, 2021 19:00:19 GMT -5
We have patients that are not on Afrezza, that are on other medication or that we are weaning off Metformin. Or that didn’t pass the breath test...but Afrezza is our flagship product. It’s the game changer like we all know. The ultimate goal is to get them on Afrezza and get them down to non-diabetic numbers.
We specialize in blood sugar control.
|
|
|
|
Post by longliner on Mar 4, 2021 19:10:03 GMT -5
What I would like to know is how does Vdex make money with such a low volume patient traffic? From White Paper.. “Note however, that Vdex is fully compensated for its medical services in treating patients. Even if an insurance plan ultimately denies coverage for the therapy, the medical provider is compensated for its services.” If insurance denies coverage, who ultimately compensates the medical provider? |
|
|
|
Post by nylefty on Mar 4, 2021 19:50:08 GMT -5
From White Paper.. “Note however, that Vdex is fully compensated for its medical services in treating patients. Even if an insurance plan ultimately denies coverage for the therapy, the medical provider is compensated for its services.” If insurance denies coverage, who ultimately compensates the medical provider? If I go to a doctor or other medical provider my insurance pays for the visit, whether or not the provider prescribes a medication. Vdex isn't selling Afrezza or any other med. It's selling the services of its providers. |
|
